A Phase II Study of ABT-751 in Patients With Breast Cancer Refractory to Taxane Regimens
Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Female
Breast Cancer
Female
Breast Cancer
Trial Information
A Phase II Study of ABT-751 in Patients With Breast Cancer Refractory to Taxane Regimens
Inclusion Criteria
Inclusion Criteria
- Stage IIIB or IV breast cancer.
- Recurrent tumor after or while on taxane therapy (taxol or taxotere).
- Able to tolerate normal activities of daily living.
- Adequate bone marrow, kidney and liver function.
Exclusion Criteria
- Pregnant or breast feeding.
- No anti-tumor therapy (including hormonal therapy or Herceptin) within 4 weeks of the
start of ABT-751 administration.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Objective Response Rate in subjects with Breast cancer
Outcome Time Frame:
1 year
Principal Investigator
Helen Eliopoulos, MD
Investigator Role:
Study Director
Investigator Affiliation:
Abbott
Authority:
United States: Food and Drug Administration
Study ID:
M02-447
NCT ID:
NCT00063102
Start Date:
November 2002
Completion Date:
August 2004
Related Keywords:
- Breast Cancer
- Breast Neoplasms
Name | Location |
|---|---|
| Oncology-Hematology Group of South Florida | Miami, Florida 33176 |
| Georgia Cancer Specialists | Decatur, Georgia 30033 |
| Texas Oncology | Dallas, Texas |
| Clinical Research Network, Inc. | Plantation, Florida 33324 |
| Northwestern University Medical School Division of Hematology/Oncology | Chicago, Illinois 60611 |
| Indiana University Cancer Center Section of of Hemtology/Oncology Indiana Cancer Pavilion | Indianapolis, Indiana 46202 |
| Northern Indiana Cancer Research Consortium | South Bend, Indiana |
| Oncology & Hemotology Associates of Kansas City, PA | Kansas City, Missouri 64111 |
